代表突变用于预测癌症药物反应.
Patrick Wall1, Trey Ideker1,2,3
1Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, United States.
Bioinformatics (Oxford, England)
|June 28, 2024
概括
通过使用定量突变得分而不是简单的基因突变状态来改善预测癌症药物反应. 这种方法提高了针对癌症向治疗的模型性能和理解.
科学领域:
- 基因组学就是基因组学.
- 计算生物学 计算生物学
- 癌症研究 癌症研究
背景情况:
- 预测癌症药物反应对于有效治疗至关重要.
- 目前的模型通常依赖于二进制基因突变状态,忽视突变严重程度.
- 不是所有基因内的突变都具有同等的生物或临床影响.
研究的目的:
- 开发和评估使用定量突变评分方法对癌症药物反应的预测模型.
- 将定量突变评分模型的性能与传统的二进制突变状态模型进行比较.
- 调查定量突变评分对各种癌症药物和标的普遍性.
主要方法:
- 使用了主要的定量突变评分方法:VEST4,CADD (基因功能影响) 和CHASMplus (癌症驱动可能性).
- 构建了结合这些定量突变特征的预测模型.
- 评估了模型在预测细胞对向疗法的反应方面的性能,包括针对BRAF-V600突变的dabrafenib.
主要成果:
- 使用定量突变得分的预测模型准确地捕获了对dabrafenib的细胞反应,优于基于二进制突变状态的模型.
- 在多种向疗法中观察到性能改善,扩大了PIK3CA,ERBB2,EGFR,PARP1和ABL1.1抑制剂的遗传指示.
- 整合定量突变特征提高了药物反应的预测性能和机制理解.
结论:
- 与二进制突变状态相比,定量突变评分为预测癌症药物反应提供了更细致和更有效的方法.
- 这种方法提高了预测模型的准确性,并加深了对癌症中药物机制的理解.
- 开发的模型和方法对各种向癌症治疗具有广泛的适用性.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


